These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Impact of the Charge Ratio on the In Vivo Immunogenicity of Lipoplexes. Heidari Z; Arora JS; Datta D; John VT; Kumar N; Bansal GP Pharm Res; 2017 Sep; 34(9):1796-1804. PubMed ID: 28560696 [TBL] [Abstract][Full Text] [Related]
30. Immunogenicity of a recombinant malaria vaccine based on receptor binding domain of Plasmodium falciparum EBA-175. Pattnaik P; Shakri AR; Singh S; Goel S; Mukherjee P; Chitnis CE Vaccine; 2007 Jan; 25(5):806-13. PubMed ID: 17045706 [TBL] [Abstract][Full Text] [Related]
31. Remarkably high antibody levels and protection against P. falciparum malaria in Aotus monkeys after a single immunisation of SPf66 encapsulated in PLGA microspheres. Rosas JE; Pedraz JL; Hernández RM; Gascón AR; Igartua M; Guzmán F; Rodríguez R; Cortés J; Patarroyo ME Vaccine; 2002 Mar; 20(13-14):1707-10. PubMed ID: 11906756 [TBL] [Abstract][Full Text] [Related]
32. A Reproducible and Scalable Process for Manufacturing a Pfs48/45 Based Singh SK; Plieskatt J; Chourasia BK; Fabra-García A; Garcia-Senosiain A; Singh V; Bengtsson KL; Reimer JM; Sauerwein R; Jore MM; Theisen M Front Immunol; 2020; 11():606266. PubMed ID: 33505395 [TBL] [Abstract][Full Text] [Related]
33. Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle. Shimp RL; Rowe C; Reiter K; Chen B; Nguyen V; Aebig J; Rausch KM; Kumar K; Wu Y; Jin AJ; Jones DS; Narum DL Vaccine; 2013 Jun; 31(28):2954-62. PubMed ID: 23623858 [TBL] [Abstract][Full Text] [Related]
34. Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals. Barr PJ; Green KM; Gibson HL; Bathurst IC; Quakyi IA; Kaslow DC J Exp Med; 1991 Nov; 174(5):1203-8. PubMed ID: 1940798 [TBL] [Abstract][Full Text] [Related]
36. Potent antibody lineage against malaria transmission elicited by human vaccination with Pfs25. McLeod B; Miura K; Scally SW; Bosch A; Nguyen N; Shin H; Kim D; Volkmuth W; Rämisch S; Chichester JA; Streatfield S; Woods C; Schief WR; Emerling D; King CR; Julien JP Nat Commun; 2019 Sep; 10(1):4328. PubMed ID: 31551421 [TBL] [Abstract][Full Text] [Related]
37. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles. Lalitha PV; Biswas S; Pillai CR; Saxena RK Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786 [TBL] [Abstract][Full Text] [Related]
38. Expression of malaria transmission-blocking vaccine antigen Pfs25 in Pichia pastoris for use in human clinical trials. Zou L; Miles AP; Wang J; Stowers AW Vaccine; 2003 Apr; 21(15):1650-7. PubMed ID: 12639486 [TBL] [Abstract][Full Text] [Related]
39. Malaria transmission blocking activity of Anopheles stephensi alanyl aminopeptidase N antigen formulated with MPL, CpG, and QS21 adjuvants. Pourhashem Z; Nourani L; Pirahmadi S; Yousefi H; J Sani J; Raz A; Zakeri S; Dinparast Djadid N; Abouie Mehrizi A PLoS One; 2024; 19(7):e0306664. PubMed ID: 38968270 [TBL] [Abstract][Full Text] [Related]
40. Adjuvant activity of polymer microparticles and Montanide ISA 720 on immune responses to Plasmodium falciparum MSP2 long synthetic peptides in mice. Mata E; Carcaboso AM; Hernández RM; Igartua M; Corradin G; Pedraz JL Vaccine; 2007 Jan; 25(5):877-85. PubMed ID: 17070628 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]